Gamco Investors INC. ET AL lessened its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 499,253 shares of the biopharmaceutical company’s stock after selling 40,850 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Bristol-Myers Squibb were worth $25,951,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Arlington Partners LLC lifted its stake in Bristol-Myers Squibb by 40.0% in the fourth quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 400 shares during the period. Cypress Capital Management LLC WY lifted its stake in Bristol-Myers Squibb by 154.7% in the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,160 shares during the period. CKW Financial Group lifted its stake in Bristol-Myers Squibb by 29.4% in the fourth quarter. CKW Financial Group now owns 2,200 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 500 shares during the period. NuWave Investment Management LLC lifted its stake in Bristol-Myers Squibb by 5,418.2% in the fourth quarter. NuWave Investment Management LLC now owns 2,428 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 2,384 shares during the period. Finally, Lavaca Capital LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $127,000. 73.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE BMY opened at $50.22 on Monday. Bristol-Myers Squibb Co has a 52 week low of $44.30 and a 52 week high of $70.05. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The company has a market cap of $81.97 billion, a P/E ratio of 12.62, a P/E/G ratio of 1.60 and a beta of 0.83.
The business also recently declared a quarterly dividend, which was paid on Friday, February 1st. Investors of record on Friday, January 4th were given a dividend of $0.41 per share. The ex-dividend date was Thursday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a yield of 3.27%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
Several equities analysts have weighed in on BMY shares. Citigroup lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $62.00 to $57.00 in a research note on Monday, October 22nd. Morgan Stanley set a $54.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Thursday, December 20th. Credit Suisse Group reissued a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. Societe Generale raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research note on Tuesday, January 15th. Finally, William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $60.21.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also: Current Ratio
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.